
Sign up to save your podcasts
Or


In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually.
(00:00) Welcome and Acknowledgement
(00:43) Meet the Expert Guests
(01:40) ALK History and Breakthroughs
(03:48) Who Gets ALK Lung Cancer
(04:57) Workup and Staging Essentials
(05:54) Patterns of Spread and Clots
(07:24) Second Generation TKIs Standard
(09:03) Long Term Toxicities
(11:07) Progression Assessment and LAT
(12:50) Lorlatinib After Progression
(15:46) Lorlatinib First Line Crown Data
(17:11) Choosing and Dosing Lorlatinib
(20:55) Managing Lorlatinib Side Effects
(22:29) Predicting Response and Follow Up
(29:30) Next Generation Inhibitors NAL
(32:04) Early Stage and Adjuvant TKIs
(36:32) Beyond TKIs Chemo and ADCs
(39:30) Patient Support and Closing
Support TOGA
Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.
---------------
Connect with TOGA
Attend an Event: https://thoraciconcology.org.au/events/
Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/
Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/
Follow Us
LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
X (Twitter): https://x.com/TOGAANZ
Instagram: https://www.instagram.com/togaanz/
YouTube: https://www.youtube.com/@Thoracic_Oncology
---------------
Acknowledgement of Country
The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
By Thoracic Oncology Group Of Australasia (TOGA)In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually.
(00:00) Welcome and Acknowledgement
(00:43) Meet the Expert Guests
(01:40) ALK History and Breakthroughs
(03:48) Who Gets ALK Lung Cancer
(04:57) Workup and Staging Essentials
(05:54) Patterns of Spread and Clots
(07:24) Second Generation TKIs Standard
(09:03) Long Term Toxicities
(11:07) Progression Assessment and LAT
(12:50) Lorlatinib After Progression
(15:46) Lorlatinib First Line Crown Data
(17:11) Choosing and Dosing Lorlatinib
(20:55) Managing Lorlatinib Side Effects
(22:29) Predicting Response and Follow Up
(29:30) Next Generation Inhibitors NAL
(32:04) Early Stage and Adjuvant TKIs
(36:32) Beyond TKIs Chemo and ADCs
(39:30) Patient Support and Closing
Support TOGA
Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.
---------------
Connect with TOGA
Attend an Event: https://thoraciconcology.org.au/events/
Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/
Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/
Follow Us
LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
X (Twitter): https://x.com/TOGAANZ
Instagram: https://www.instagram.com/togaanz/
YouTube: https://www.youtube.com/@Thoracic_Oncology
---------------
Acknowledgement of Country
The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

27 Listeners

3 Listeners